Sergei Kashirny, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 44 manufacturers reported payments, led by Eisai Inc. at 32.7% of the total. Reporting peaked in 2022 at $8,560 and has fallen 87.2% since, to $1,094 in 2025.
Across 328 payments — averaging $62.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$7K
- SK Life Science, Inc.$3K
- Neuropace, Inc.$2K
- EMD Serono, Inc.$1K
- UCB, Inc.$1K
- Jazz Pharmaceuticals Inc.$658
- plus $5K from 38 others
What the payments were for
- Consulting fees$8,09040%
- Speaking & faculty fees$3031%
- Travel & lodging$2,23911%
- Food & beverage$9,69648%
- Education$810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fycompa$6,384
- Cenobamate$2,240
- RNS Neurostimulator Kit$1,592
- Mavenclad$333
- Epidiolex$274
- AUBAGIO$240
- XCOPRI$227
- ZEPOSIA$219
- Austedo XR$213
- TYSABRI$150
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$144
- VISUALASE$124
- SOLIRIS$112
How this compares
$20,409 in reported general payments places this provider in the 85th percentile of 59 neurology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 329 | $430,775 |
| EpidiolexCannabidiol (Cbd) | 75 | $246,298 |
| AptiomEslicarbazepine Acetate | 74 | $168,154 |
| OnfiClobazam | 31 | $115,427 |
| Plegridy PenPeginterferon Beta-1a | 13 | $93,334 |
| BriviactBrivaracetam | 62 | $91,588 |
| FycompaPerampanel | 63 | $80,752 |
| VimpatLacosamide | 36 | $62,555 |
| CopaxoneGlatiramer Acetate | 11 | $61,122 |
| Rufinamide | 14 | $52,418 |
| ZonegranZonisamide | 13 | $50,746 |
| Lacosamide | 357 | $49,173 |
| Lamotrigine ErLamotrigine | 130 | $43,188 |
| KeppraLevetiracetam | 18 | $41,398 |
| ValtocoDiazepam | 36 | $36,333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $3,462 | $430,775329 claims |
| UCB, Inc.Briviact, Vimpat, Nayzilam | $1,009 | $176,791130 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $71 | $168,15474 claims |
| Lundbeck LLCOnfi | $20 | $115,42731 claims |
| Eisai Inc.Fycompa | $6,675 | $80,75263 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $302 | $61,12211 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr, Trokendi Xr | $407 | $60,93327 claims |
| Neurelis, Inc.Valtoco | $170 | $36,33336 claims |
| Upsher-smith Laboratories LLCTopiramate | $51 | $1,53673 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 59 neurology providers in Idaho.
Other neurology in Boise
- Anant WadhwaBoise$6K
- Jackie WhitesellBoise$2K
- Brittany LovascioBoise$2K
- Benjamin StewartBoise$2K
- Matthew TechyBoise$2K
- Kelly BlockBoise$2K
- Thomas StrobelBoise$1K
- Lukas ClarkBoise$1K
- James WhitesideBoise$1K
- Daniel SimmonsBoise$729
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.